Our researchers have demonstrated high impact publications and are recipients of NHMRC, Cancer Institute, Lincoln Centre, Cancer Council, University of Sydney Research Fund, Ramsay Health, Rebecca Cooper Foundation, Avant Foundation, Phaeo/Para Alliance and HCF Research Foundation grants.
Our senior researchers have outstanding H-indexes and demonstrate a >200+ publication list.
Our aim is to establish a comprehensive personalised approach to thyroid cancer management across the full spectrum of the disease, utilising evidence-based algorithms.
Our overarching goal aims to prevent the unnecessary overtreatment of low risk thyroid cancer (minimising unnecessary harm) and to develop a personalised genomic and clinicopathologic profile of advanced thyroid cancer to expedite effective targeted therapy and improve patient outcomes.
Our group has expertise in translational research as well as clinical experience in endocrine cancer. We already have a strategic pipeline of research across the spectrum of thyroid cancer with many projects involving junior scientists and clinicians.
Our current research projects include analysis of ctDNA, tailoring radioactive iodine therapy, risk stratification of thyroid nodules, machine learning models, pathological grading of endocrine cancers, utility of DOTATE-PET scans in thyroid cancer diagnosis.
With your help, our translational research can be accelerated and improve the quality of life and survival outcomes for patients with thyroid cancer.
If you are considering making a major gift or leaving a gift in will for our research, please contact one of our development professionals who will be able to discuss how you can give and the impact your gift could have.
We collaborate with many other colleagues across NSW including paediatrics, implementation science and oncology. Contact us to find out more.